# Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
Canonical URL: https://biopharmsignal.com/news/ANAB/anaptys-to-participate-at-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference
Ticker: ANAB
Company: AnaptysBio, Inc.
Source: AnaptysBio, Inc.
Published: 2026-05-04 20:15 EST
Original Source URL: https://ir.anaptysbio.com
## Summary

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for  Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate

## Article Body
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for  Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate
## Recent Company News
- 2026-05-12 20:15 EST — [Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ANAB/anaptys-announces-first-quarter-2026-financial-results-and-provides-business-update) — Source: AnaptysBio, Inc.
- 2026-05-11 13:15 EST — [Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors](https://biopharmsignal.com/news/ANAB/anaptys-appoints-chris-murphy-as-chief-financial-officer-and-owen-hughes-to-board-of-directors) — Source: AnaptysBio, Inc.
- 2026-05-04 20:15 EST — [Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference](https://biopharmsignal.com/news/ANAB/anaptys-to-participate-at-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference) — Source: AnaptysBio, Inc.
- 2026-04-24 19:40 EST — [Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim](https://biopharmsignal.com/news/ANAB/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaro-s-anticipatory-breach-claim) — Source: AnaptysBio, Inc.
- 2026-04-20 13:15 EST — [Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations](https://biopharmsignal.com/news/ANAB/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations) — Source: AnaptysBio, Inc.
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)